← Back to Search

Anticholinergic

Active Group for Drooling (GLYCOPAR Trial)

Phase 2
Waitlist Available
Led By Tiago Mestre, MSc, MD
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

GLYCOPAR Trial Summary

Sialorrhea is a frequently occurring problem with detrimental effect on quality of life in 25% of PD patients. Currently, there is no intervention approved for sialorrhea in Parkinsons and evidence is only available for a 30-day effect or less. We hypothesize that glycopyrrolate will have a lasting effect in the reduction of sialorrhea in PD patients.

Eligible Conditions
  • Drooling
  • Parkinson's Disease

GLYCOPAR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean sialorrhea related-disability at end of treatment (day 90) measured by the patient/caregiver-rated ROMP-saliva.
Secondary outcome measures
Mean score in sialorrhea severity at end of treatment (day 90) measured by the sialorrhea scoring scale
Proportion of participants with a reduction of severity of sialorrhea in at least one point from baseline to end of treatment (day 90), measured by the MDS-UPDRS, item 2.2.

GLYCOPAR Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active GroupActive Control1 Intervention
This arm will receive the study drug glycopyrrolate.
Group II: Placebo GroupPlacebo Group1 Intervention
Control arm to receive placebo

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
561 Previous Clinical Trials
2,785,663 Total Patients Enrolled
Tiago Mestre, MSc, MDPrincipal InvestigatorThe Ottawa Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease
2016. "Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02382198.
All > Parkinson
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top